Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Myelodysplastic Syndromes 323Leukemia, Myeloid, Acute 276Leukemia, Myelogenous, Chronic, BCR-ABL Positive 244Leukemia 116Myeloproliferative Disorders 106Primary Myelofibrosis 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 100Leukemia, Myelomonocytic, Chronic 78Polycythemia Vera 73Hematologic Neoplasms 67Multiple Myeloma 50Neoplasms 41Lymphoma, Non-Hodgkin 40Thrombocythemia, Essential 39Hematologic Diseases 38Leukemia, Lymphocytic, Chronic, B-Cell 37Recurrence 35Lymphoma 32Leukemia, Myeloid, Chronic-Phase 31Mastocytosis, Systemic 26Bone Marrow Diseases 25Leukemia, Myeloid 23Blast Crisis 23Anemia, Refractory, with Excess of Blasts 23Hodgkin Disease 21Bronchiolitis Obliterans Syndrome 16Mastocytosis 15Philadelphia Chromosome 14Leukemia, Mast-Cell 13Graft vs Host Disease 13

Interventions

masitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Blushing × Myeloid × Clear all
NCT04333108 2023-05-06

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

AB Science

Phase 3 Unknown
140 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT00814073 2019-12-03

AB06006

AB Science

Phase 3 Completed
135 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡